Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OmniVis was a private biotechnology and diagnostic-device company that developed handheld pathogen detection systems intended to bring laboratory-grade molecular testing closer to the point of need. Its core product platform, iSpyDx, was positioned as a low-cost portable device for detecting pathogens in food, water, plant, and potentially human samples in roughly 30 to 40 minutes without specialized lab infrastructure. The company emerged from Purdue University-affiliated research and highlighted applications including cholera detection in water as well as broader DNA and RNA pathogen testing. OmniVis appears to have focused on commercializing rapid molecular diagnostics rather than therapeutics, and third-party business databases now indicate that the company is permanently closed. The company was not a drug developer and did not have a traditional therapeutic pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on OmniVis.